Kabipac Glucosalino

Sodium Chloride, the active ingredient in Kabipac Glucosalino, is an IV electrolyte solution presented as an injectable solution for intravenous use. It provides sodium, chloride, and glucose to help restore fluid volume and electrolyte balance in patients requiring fluid replacement or hypoglycemia prevention.

GNH USA supplies Kabipac Glucosalino as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for each batch, ensuring traceability and patient safety across global markets.

Kabipac Glucosalino is used in clinical settings to address fluid and electrolyte disturbances and low blood glucose. - Fluid replacement: Restores intravascular volume in patients with dehydration or blood loss. - Electrolyte replenishment: Supplies sodium and chloride to correct electrolyte imbalances. - Hypoglycemia prevention or treatment: Provides glucose to raise blood sugar in at‑risk patients.

Adverse reactions may occur with any intravenous therapy and should be monitored.

Common Side Effects: - Phlebitis or local vein irritation - Infiltration at the infusion site - Mild hypernatremia - Transient hyperglycemia - Electrolyte imbalance (e.g., chloride shift) - Local discomfort or pain

Serious or Rare Side Effects: - Anaphylactic reaction - Severe hypernatremia leading to neurologic symptoms - Severe hyperglycemia with osmotic diuresis - Fluid overload causing pulmonary edema - Cardiac arrhythmia due to electrolyte shifts - Sepsis from contaminated solution

Proper assessment and monitoring are essential when administering this injectable solution. - Assess electrolyte status before administration: verify baseline sodium, chloride, and glucose levels. - Monitor blood glucose during infusion: adjust rate if hyperglycemia develops. - Adjust infusion rate in patients with cardiac failure: avoid rapid volume expansion. - Avoid rapid bolus in neonates and small children: use controlled infusion. - Use aseptic technique to prevent infection: ensure sterile handling of the vial. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Certain concomitant medications may modify the effects of the solution.

Major Interactions (Avoid): - Concurrent hypertonic saline: risk of severe hypernatremia. - High‑dose insulin therapy: may cause rapid glucose shifts. - Loop diuretics: can exacerbate electrolyte loss.

Moderate Interactions (Monitor Closely): - Corticosteroids: may increase sodium retention. - Beta‑agonists: can affect potassium levels. - ACE inhibitors or ARBs: influence fluid balance and blood pressure. - Oral hypoglycemic agents: monitor for additive glucose‑lowering effect.